Financial Results Declaration
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Phaarmasia Limited announced its audited financial results for FY25, reporting revenue from operations of ₹2,436.88 lakhs, down from ₹3,059.33 lakhs in FY24 — a decline of about 20.3%. The company slipped deeper into the red with a net loss of ₹(158.94) lakhs versus ₹(51.82) lakhs in the previous year, and loss before tax widened to ₹(160.27) lakhs from ₹(54.59) lakhs. Basic EPS worsened to ₹(2.33) from ₹(0.76). The balance sheet shrank — total assets fell to ₹2,156.01 lakhs from ₹3,144.78 lakhs, largely on lower inventories, receivables, and payables. Cash from operations was effectively negative at ₹(0.36) lakhs, and closing cash dropped to ₹36.42 lakhs. The statutory auditor, Sathuluri & Co, issued an unmodified (clean) opinion.
Sharply falling revenue combined with widening losses and a shrinking balance sheet signals ongoing operational stress for shareholders, though the clean audit opinion removes any immediate governance red flag.